Condensed Consolidated Statements of Income (Unaudited) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended	6 Months Ended
Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues:
Product, net	$ 2,056,292	$ 1,385,918	$ 3,799,057	$ 2,481,697
Unconsolidated joint business	303,296	288,785	600,181	553,391
Other	61,864	48,770	151,965	103,481
Total revenues	2,421,452	1,723,473	4,551,203	3,138,569
Cost and expenses:
Cost of sales, excluding amortization of acquired intangible assets	291,887	230,728	571,132	364,477
Research and development	447,273	327,463	976,157	611,803
Selling, general and administrative	576,622	431,012	1,088,296	783,610
Amortization of acquired intangible assets	116,826	82,225	260,084	133,526
Collaboration profit sharing	0	0	0	85,357
(Gain) loss on fair value remeasurement of contingent consideration	4,019	(5,163)	3,220	(2,886)
Total cost and expenses	1,436,627	1,066,265	2,898,889	1,975,887
Gain on sale of rights	3,900	5,319	7,759	10,370
Income from operations	988,725	662,527	1,660,073	1,173,052
Other income (expense), net	4,861	(10,428)	(740)	(24,885)
Income before income tax expense and equity in loss of investee, net of tax	993,586	652,099	1,659,333	1,148,167
Income tax expense	268,521	159,140	446,935	224,648
Equity in loss of investee, net of tax	1,933	2,289	9,538	6,100
Net income	723,132	490,670	1,202,860	917,419
Net income (loss) attributable to noncontrolling interests, net of tax	8,626	0	8,398	0
Net income attributable to Biogen Idec Inc.	$ 714,506	$ 490,670	$ 1,194,462	$ 917,419
Net income per share:
Basic earnings per share attributable to Biogen Idec Inc.	$ 3.02	$ 2.07	$ 5.05	$ 3.87
Diluted earnings per share attributable to Biogen Idec Inc.	$ 3.01	$ 2.06	$ 5.03	$ 3.85
Weighted-average shares used in calculating:
Basic earnings per share attributable to Biogen Idec Inc.	236,661	237,484	236,729	237,162
Diluted earnings per share attributable to Biogen Idec Inc.	237,401	238,743	237,634	238,543

Expense for payments made to the collaborative partner for their applicable share of net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties paid on behalf of the collaboration. As sales under the collaborative agreement increase, our collaboration profit sharing expense will increase.

No definition available.